Literature DB >> 15956601

Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface.

Myrna C Bonaldo1, Richard C Garratt, Renato S Marchevsky, Evandro S F Coutinho, Alfredo V Jabor, Luís F C Almeida, Anna M Y Yamamura, Adriana S Duarte, Prisciliana J Oliveira, Jackeline O P Lizeu, Luiz A B Camacho, Marcos S Freire, Ricardo Galler.   

Abstract

The yellow fever (YF) 17D vaccine is a live attenuated virus. Three-dimensional (3D) homology modeling of the E protein structure from YF 17D virus and its comparison with that from tick-borne encephalitis virus revealed that it is possible to accommodate inserts of different sizes and amino acid compositions in the flavivirus E protein fg loop. This is consistent with the 3D structures of both the dimeric and trimeric forms in which the fg loop lies exposed to solvents. We demonstrate here that YF 17D viruses bearing foreign humoral (17D/8) and T-cell (17D/13) epitopes, which vary in sequence and length, displayed growth restriction. It is hypothesized that interference with the dimer-trimer transition and with the formation of a ring of such trimers in order to allow fusion compromises the capability of the E protein to induce fusion of viral and endosomal membranes, and a slower rate of fusion may delay the extent of virus production. This would account for the lower levels of replication in cultured cells and of viremia in monkeys, as well as for the more attenuated phenotype of the recombinant viruses in monkeys. Testing of both recombinant viruses (17D/8 and 17D/13) for monkey neurovirulence also suggests that insertion at the 17D E protein fg loop does not compromise the attenuated phenotype of YF 17D virus, further confirming the potential use of this site for the development of new live attenuated 17D virus-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956601      PMCID: PMC1143750          DOI: 10.1128/JVI.79.13.8602-8613.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Assessment of protein models with three-dimensional profiles.

Authors:  R Lüthy; J U Bowie; D Eisenberg
Journal:  Nature       Date:  1992-03-05       Impact factor: 49.962

2.  WHAT IF: a molecular modeling and drug design program.

Authors:  G Vriend
Journal:  J Mol Graph       Date:  1990-03

3.  Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation.

Authors:  C M Rice; A Grakoui; R Galler; T J Chambers
Journal:  New Biol       Date:  1989-12

4.  Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model.

Authors:  C W Mandl; F Guirakhoo; H Holzmann; F X Heinz; C Kunz
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

5.  The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination.

Authors:  I S Levenbook; L J Pelleu; B L Elisberg
Journal:  J Biol Stand       Date:  1987-10

6.  Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution.

Authors:  C M Rice; E M Lenches; S R Eddy; S J Shin; R L Sheets; J H Strauss
Journal:  Science       Date:  1985-08-23       Impact factor: 47.728

7.  A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.

Authors:  F Guirakhoo; Z Zhang; G Myers; B W Johnson; K Pugachev; R Nichols; N Brown; I Levenbook; K Draper; S Cyrek; J Lang; C Fournier; B Barrere; S Delagrave; T P Monath
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.

Authors:  F Guirakhoo; K Pugachev; Z Zhang; G Myers; I Levenbook; K Draper; J Lang; S Ocran; F Mitchell; M Parsons; N Brown; S Brandler; C Fournier; B Barrere; F Rizvi; A Travassos; R Nichols; D Trent; T Monath
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  Structure of the dengue virus envelope protein after membrane fusion.

Authors:  Yorgo Modis; Steven Ogata; David Clements; Stephen C Harrison
Journal:  Nature       Date:  2004-01-22       Impact factor: 49.962

Review 10.  Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis.

Authors:  Ching-Juh Lai; Thomas P Monath
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

View more
  16 in total

1.  A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.

Authors:  Peter J Bredenbeek; Richard Molenkamp; Willy J M Spaan; Vincent Deubel; Phillippe Marianneau; Maria S Salvato; Dmitry Moshkoff; Juan Zapata; Ilia Tikhonov; Jean Patterson; Ricardo Carrion; Anysha Ticer; Kathleen Brasky; Igor S Lukashevich
Journal:  Virology       Date:  2006-01-18       Impact factor: 3.616

Review 2.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

3.  Improved genetic stability of recombinant yellow fever 17D virus expressing a lentiviral Gag gene fragment.

Authors:  Marlon G Veloso de Santana; Patrícia C C Neves; Juliana Ribeiro dos Santos; Noemia S Lima; Alexandre A C dos Santos; David I Watkins; Ricardo Galler; Myrna C Bonaldo
Journal:  Virology       Date:  2014-02-08       Impact factor: 3.616

4.  Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.

Authors:  Xiaohong Jiang; Tim J Dalebout; Peter J Bredenbeek; Ricardo Carrion; Kathleen Brasky; Jean Patterson; Marco Goicochea; Joseph Bryant; Maria S Salvato; Igor S Lukashevich
Journal:  Vaccine       Date:  2010-12-08       Impact factor: 3.641

5.  The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques--implications for recombinant vaccine design.

Authors:  Philip A Mudd; Shari M Piaskowski; Patricia C Costa Neves; Richard Rudersdorf; Holly L Kolar; Christopher M Eernisse; Kim L Weisgrau; Marlon G Veloso de Santana; Nancy A Wilson; Myrna C Bonaldo; Ricardo Galler; Eva G Rakasz; David I Watkins
Journal:  Immunogenetics       Date:  2010-07-07       Impact factor: 2.846

6.  Visualization of feline calicivirus replication in real-time with recombinant viruses engineered to express fluorescent reporter proteins.

Authors:  Eugenio J Abente; Stanislav V Sosnovtsev; Karin Bok; Kim Y Green
Journal:  Virology       Date:  2010-02-04       Impact factor: 3.616

7.  Engineering the Japanese encephalitis virus RNA genome for the expression of foreign genes of various sizes: implications for packaging capacity and RNA replication efficiency.

Authors:  Sang-Im Yun; Yu-Jeong Choi; Xiao-Fang Yu; Jae-Young Song; Young-Hak Shin; Young-Ran Ju; Seok-Yong Kim; Young-Min Lee
Journal:  J Neurovirol       Date:  2007-12       Impact factor: 2.643

Review 8.  Current status and future prospects of yellow fever vaccines.

Authors:  Andrew S Beck; Alan D T Barrett
Journal:  Expert Rev Vaccines       Date:  2015-09-14       Impact factor: 5.217

9.  The C Terminus of the Core β-Ladder Domain in Japanese Encephalitis Virus Nonstructural Protein 1 Is Flexible for Accommodation of Heterologous Epitope Fusion.

Authors:  Li-Chen Yen; Jia-Teh Liao; Hwei-Jen Lee; Wei-Yuan Chou; Chun-Wei Chen; Yi-Ling Lin; Ching-Len Liao
Journal:  J Virol       Date:  2015-11-11       Impact factor: 5.103

Review 10.  Advanced vaccine candidates for Lassa fever.

Authors:  Igor S Lukashevich
Journal:  Viruses       Date:  2012-10-29       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.